Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2020-03-16 Earnings Release
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 16, 2020, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the year ended December 31, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished and not filed, indicating this is an announcement of financial results rather than the full report itself. The document length is 3535 characters, which is relatively short and consistent with an announcement rather than a full earnings release or annual report. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to earnings releases or financial results announcements. Since the document is primarily an announcement of the earnings release and not the earnings release itself, the appropriate classification is Earnings Release (ER).
2020-03-16 English
10-K
Annual Report FY 2019
2020-03-13 English
8-K LOAN AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a loan and security agreement with lenders, detailing the terms of the loan, interest rates, covenants, and issuance of warrants. It also includes sections on creation of a direct financial obligation and unregistered sales of equity securities. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is an announcement of a financing event and related agreements. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8771 characters) supports that this is a substantive filing, not a brief announcement or certification. Confidence is high due to clear identification of loan agreement details and financing terms.
2020-03-03 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-27 English
SC 13G/A
Major Shareholding Notification
2020-02-14 English
SC 13G/A
Major Shareholding Notification
2020-02-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.